The Related Factors and Clinical Predictive Value of Left Atrial Spontaneous Echo Contrast in Patient with Nonvalvular Chronic Atrial Fibrillation
DOI:
https://doi.org/10.17140/HROJ-2-108Keywords:
Left atrial spontaneous echo contrast, Atrial fibrillation, Transesophageal EchocardiographyAbstract
Background: To investigate left atrial or left atrial appendage spontaneous echo by transesophageal
echocardiography for clinical risk assessment, providing an important basis for guiding
treatment and so on.
Methods: Select 113 atrial fibrillation patients who did not have formal warfarin treatment in
2011-2014 and did transesophageal echocardiography, after excluding substandard patients, 92
patients were divided into LASEC positive group (n=63) and negative group (n=29). Analyses
the clinical features and echocardiographic parameters. Evaluate the diagnostic value with
results of multivariate analysis.
Results: The study found a significant difference (P<0.05) between the two groups in the type
of AF (permanent AF), hypertension, left atrial diameter, left ventricular diastolic function,
among these factors, persistent atrial fibrillation, left atrial diameter >40 mm and hypertension
have a extremely significant difference (P<0.01). CHA2DS2-VASC score, D-dimer in plasma
have a predictive value for LASEC patients with atrial fibrillation.
Conclusion: Patients with persistent AF have a higher LASEC incidence, LASEC has clinical
predictive value, there are certain guiding significance in clinical practice.
References
Fatkin D, Kell RP, Feneley MP. Relation between left atrial appendage blood flow velocity aspontaneous echocardioghraph-ic contrast and thromboembolic risk in vivo. J Am Coll Cardial. 1994; 23(4): 961-969. doi: 10.1016/0735-1097(94)90644-0
Zhang Y, Zhang M, Ge ZM. International echocardiography. Shandong. 2000; 2000: 477.
Bernhardt P, Schmidt H. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk. JACC. 2005; 45 (11): 1807-1812. doi: 10.1016/j.jacc.2004.11.071
Sahin T, Acar E, Celikyurt U, et al. Relation of hs-CRP and BNP levels with the atrial spontaneous echo contrast and thrombi in permanent atrial fibrillation patients with different etiologies. 2012; 18(2): CR78–CR87. doi: 10.12659/MSM.882461
Wan A, Harrison JK, Bashore TM, et al. Correlation between quantitative left atrial spontaneous echocardiography contrast and intact fibrinoen levels in mitral stenosis. J Am Soc Echocardio-raphy. 2001; 14(4): 285-291. doi: 10.1067/mje.2001.111266
Mahe I, Drouet L, Simoneau G, et al. D-dimer can predict sur-vival in patients with chronic atrial fibrillation. J Blood Coagul Fibrinolysis. 2004; 15(5): 413-417.
Lixin RAO, Muhuab Li. The effect of warfarin in treatment atrial fibrillation with cerebrella infarction and the change of D-Dimmer. Chinese Clinic Neorology. 2010; 13(20): 5-7.
Healey JS, Connolly SJ. Atrial fibrillation : hypertension as a causative agent risk factor for complications and potential therapeutic target. Am J Cardiol. 2003; 91(10A): 9G-14G. doi: 10.1161/CIRCULATIONAHA.107.760777
Cairns JA. CHA DS -VASC had better discrimination than CHADS2 for predicting risk for thromboembolism in atrial fi-brillation. Ann Intern Med. 2011; 154(10): JC5-JC13.
Doukky R, Garcia-Sayan E. The value of diastolic function parameters in the prediction of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. J Cardiovascular Ultrasound. 2014; 12: 10. doi: 10.1186/1476-7120-12-10
Daniel WG, Nellessen V, Schroder E, et al. Left Atrial spon-taneous echo contrast in mitral valve disease: An indicator for an increased thromboembolic risk. J Am Coll Cardiol. 1988; 11(6): 1204. doi: 10.1016/0735-1097(88)90283-5
Hirabaya S, Mochizuki N, Miymto N, et al. Spontaneous contrast echo raises and warfarin treatment reduces the risk of cerebral embolism in patient with nonvalvular chronic atrial fi-brillation. Circulation. 1992; 86(4 suppl): I-398. Heart Res Open J Page 50
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.